Clinical Trials

Status
Published

Recently Activated

SHOW MORE
Open
Accrual
0%
SWOG Clinical Trial Number
S1823

A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors

Status Notes
The study is open for registration effective 6/1/20.
Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06-01-2020
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1914

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

Status Notes
This study is open to accrual effective March 25, 2020.
Research Committee(s)
Lung Cancer
Activated
03-25-2020
ClinicalTrials.gov Registry Number
04214262
Open
Phase
II
Accrual
2%
SWOG Clinical Trial Number
S1900B

A PHASE II STUDY OF LOXO-292 IN PATIENTS WITH RET FUSION-POSITIVE STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Status Notes
S1900B will open to accrual February 10, 2020, effective 12:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
02-10-2020
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-GY020

Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (DMMR) Endometrioid Endometrial Cancer

Research Committee(s)
Early Therapeutics & Rare Cancers
Gynecologic Cancer
Activated
02-07-2020
ClinicalTrials.gov Registry Number
04214067
Open
Accrual
30%
SWOG Clinical Trial Number
S1900C

A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)

Status Notes
S1900C will open to accrual January 16, 2020, effective 2:00 pm PST.

This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
01-16-2020
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1827

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Status Notes
This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
01-10-2020
ClinicalTrials.gov Registry Number
04155034